Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hut 8 Corp (HUT) vs Eli Lilly And Co (LLY) Price & Performance

Hut 8 CorpTrade
Eli Lilly And CoTrade

Price performance (Past 24H)

Key statistics

Hut 8 Corp vs Eli Lilly And Co — how do they compare? Hut 8 Corp trades at $90.46 (market cap $10.94B), while Eli Lilly And Co trades at $1,215.31 (market cap $1.08T). The key difference: Eli Lilly And Co is far larger — about 98.7× Hut 8 Corp's market cap, and Eli Lilly And Co pays a 0.57% dividend while Hut 8 Corp pays none. Which is the better fit depends on your goals.

HUTLLY
Market Cap
$10.94B$1.08T
Sector
TechnologyHealth
52-Week High
$133.02$1.24K
52-Week Low
$21.37$639.43
Enterprise Value
$18.38B$1.13T
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hut 8 Corp

HUT trades at $93.91, up 9.63% today amid a broader neocloud stock rally. The stock shows bearish technical signals with support at $87 and resistance at $92. Fundamentally, revenue grew 81% year-over-year in Q2 2026 to $74 million, but net losses persist with a -188.59% margin. The company is transitioning to an AI data center focus, securing $26.6 billion in contracted backlog and $7.5 billion in project financing.

Outlook is polarized: strong analyst buy consensus (93.75%) and a $165.11 price target reflect optimism in AI infrastructure growth, but high valuation ratios and persistent losses pose risks. Execution on Beacon Point commercialization and debt management are critical for upside.

Eli Lilly And Co

Eli Lilly (LLY) trades at $1,221.21, down 0.84% today, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The stock shows technical strength with bullish moving averages and support at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 48% revenue growth in Q2 2026. Recent news highlights the company's aggressive protection of its obesity drug pipeline against black market sales.

LLY presents a compelling growth story with dominant market positioning in weight-loss drugs and strong analyst support (73% buy ratings). Key risks include regulatory scrutiny and competitive pressures, but the company's raised guidance and pipeline advancements support continued upside toward the $1,380 consensus target.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Hut 8 Corp

Hut 8 is one of North America's largest digital asset miners and infrastructure providers. It operates diversified data centers supporting Bitcoin mining and high-performance computing (HPC) for AI.

Read more on HUT

About Eli Lilly And Co

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer

Read more on LLY